HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

February 2019

Potential Two-Dose Dalbavancin Treatment for Osteomyelitis

February 12, 2019

In the Literature

Although dalbavancin is currently approved by the US Food and Drug Administration for the treatment of skin and soft tissue infections, its distinctive pharmacokinetic profile has piqued curiosity regarding its place in therapy for infections requiring long durations of antibiotics, such as osteomyelitis.

Duration of Antibiotic Therapy for Uncomplicated Gram-Negative Bacteremia: Seven Is the New Fourteen

February 11, 2019

In the Literature

The treatment duration for uncomplicated gram-negative bloodstream infections (BSIs) has traditionally ranged from 7 to 14 days. However, recent retrospective studies and meta-analyses have observed no differences in clinical outcomes in patients treated with shorter courses compared with prolonged courses, especially with urinary sources of infection.